Skip to content
Screener

Neuropace, Inc. NPCE Deferred Revenue

Deferred Revenue at other companies

LivaNova logo
LivaNovaLIVN
$13.86M+24.0%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$1.81M+12.1%
Neuronetics logo
NeuroneticsSTIM
$58K
ITG
Integer HoldingsITGR
$5.38M+32.5%
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$22.8M+17.1%
Gross profit$18.9M+16.6%
Operating income-$5.1M+37.2%
Net income-$6.2M+28.3%
EPS (diluted)-$0.18+30.8%

Balance sheet

See full
Cash & equivalents$12.8M-44.4%
Total debt$69.9M-2.2%
Total equity$11.9M-38.9%
Total assets$97.0M-8.6%

Cash flow

See full
Operating cash flow-$3.9M-87.1%
CapEx$125.0K-25.6%
Free cash flow-$4.0M-78.7%

Valuation

See full
Market cap$505.61M+73.4%
Enterprise value$562.76M+65.5%
P/S5.1×+1.7×

Profitability

See full
Gross margin79.6%+2.6pp
Operating margin-15.3%-4.3pp
Net margin-19.3%-5.2pp
FCF margin-12.2%-3.3pp

Returns & leverage

See full
Return on equity-122.1%-28.9pp
Debt / equity5.9×+2.2×
Current ratio4.9×-0.5×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 4:33 PM EDT
Fiscal quarter
Q4 FY2030
Calendar quarter
Q4 2030
Accession
0001528287-26-000030

FAQ

What is Neuropace, Inc.'s deferred revenue?
Neuropace, Inc. (NPCE) reported deferred revenue of $123K in Q2 2026.
How has Neuropace, Inc.'s deferred revenue changed year-over-year?
Neuropace, Inc.'s deferred revenue decreased by 82.3% year-over-year, from $696K to $123K.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.

Ask your AI about Neuropace, Inc.'s deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude